EN
登录

ESMO 2026前瞻迈威生物将公布靶向 Nectin-4的 ADC药物 9MW2821在经 ADC预处理的三阴性乳腺癌中的临床结果

ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast Cancer

CISION 等信源发布 2026-10-19 10:00

可切换为仅中文


SHANGHAI

上海

,

,

Oct. 18, 2026

2026年10月18日

/PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present Phase II clinical data on

/美通社/ -- 迈威生物(688062.SH,02493.HK)是一家创新驱动、拥有完整产业链的生物制药公司,将公布其二期临床数据

its Nectin

它的Nectin

-4-targeting antibody-drug conjugate (ADC) 9MW2821 (Bulumtatug Fuvedotin, 'BFv') in locally advanced or metastatic triple-negative breast cancer (TNBC) as an oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress. The study focuses on patients previously treated with an ADC carrying a topoisomerase I inhibitor payload (hereinafter 'Topo I ADC-pretreated').

-4靶向抗体药物偶联物(ADC)9MW2821(Bulumtatug Fuvedotin,简称“BFv”)在局部晚期或转移性三阴性乳腺癌(TNBC)中的研究结果将以口头报告形式在2026年欧洲肿瘤内科学会(ESMO)大会上发表。该研究聚焦于既往接受过携带拓扑异构酶I抑制剂载荷的ADC治疗的患者(以下简称“Topo I ADC预处理”)。

The abstract is now available on the congress website..

摘要现已在大会网站上发布。

The study (CTR20242376) is designed to evaluate the efficacy and safety of 9MW2821 as monotherapy or in combination with a PD-1 monoclonal antibody in patients with locally advanced or metastatic TNBC. As of April 10, 2026, among 60 efficacy-evaluable Topo I ADC-pretreated patients, the objective response rate (ORR) was 30.0%, the disease control rate (DCR) was 80.0%, the median progression-free survival (mPFS) was 3.7 months, the median duration of response (mDOR) was 8.7 months, and the median overall survival (mOS) was not yet mature.

该研究(CTR20242376)旨在评估9MW2821作为单药或联合PD-1单克隆抗体在局部晚期或转移性三阴性乳腺癌(TNBC)患者中的疗效和安全性。截至2026年4月10日,在60名可评估疗效的既往接受过拓扑异构酶I抗体偶联药物(Topo I ADC)治疗的患者中,客观缓解率(ORR)为30.0%,疾病控制率(DCR)为80.0%,中位无进展生存期(mPFS)为3.7个月,中位缓解持续时间(mDOR)为8.7个月,中位总生存期(mOS)数据尚未成熟。

No new safety signals were observed during this follow-up period. The study results indicate that 9MW2821 has a manageable safety profile and positive therapeutic effects in patients with TNBC..

在此随访期间未观察到新的安全性信号。研究结果表明,9MW2821在三阴性乳腺癌(TNBC)患者中具有可控的安全性特征和积极的治疗效果。

In 2024, an estimated 375,800 women in China were newly diagnosed with breast cancer and approximately 73,000 died of the disease

2024年,中国估计有375,800名女性新确诊乳腺癌,约73,000人死于该病。

[1]

[1]

. TNBC accounts for approximately 15%–20% of all breast cancers and is highly aggressive with a poor prognosis. Currently, all ADCs approved for TNBC use a topoisomerase I inhibitor payload. After progression on these agents, chemotherapy remains the mainstay of care and new treatment options are urgently needed..

三阴性乳腺癌(TNBC)约占所有乳腺癌的15%–20%,具有高度侵袭性且预后不良。目前,所有获批用于TNBC的抗体偶联药物(ADC)均采用拓扑异构酶I抑制剂作为载荷。在这些药物治疗进展后,化疗仍是主要的治疗手段,亟需新的治疗选择。

[1] Xia C, Li H, Wu C, Chen W. Cancer burden and control in China. Nat Rev Clin Oncol. 2026. doi:10.1038/s41571-026-01165-8

[1] 夏C,李H,吴C,陈W. 中国的癌症负担与控制. Nat Rev Clin Oncol. 2026. doi:10.1038/s41571-026-01165-8

About 9MW2821

关于 9MW2821

9MW2821 is a Nectin-4-targeting ADC independently developed by Mabwell on its proprietary ADC development platform. It is currently conducting multiple clinical studies for several indications including urothelial carcinoma (UC), cervical cancer (CC), triple-negative breast cancer (TNBC), and esophageal cancer (EC), with a cumulative clinical enrollment of over 2,200 patients.

9MW2821 是迈博威尔在其专有抗体偶联药物(ADC)开发平台上自主研发的一款靶向 Nectin-4 的 ADC。目前,该药正在针对尿路上皮癌(UC)、宫颈癌(CC)、三阴性乳腺癌(TNBC)和食管癌(EC)等多种适应症开展多项临床研究,累计临床入组患者超过 2,200 例。

Currently, four pivotal Phase III clinical trials of 9MW2821 are underway, including UC monotherapy and combination therapy, CC monotherapy, and monotherapy for topoisomerase I inhibitor-payload ADC-pretreated TNBC. 9MW2821 has been granted Breakthrough Therapy Designation by the Center for Drug Evaluation (CDE) for UC, both as monotherapy and in combination therapy.

目前,9MW2821的四项关键III期临床试验正在进行中,包括尿路上皮癌(UC)的单药治疗和联合治疗、胆道癌(CC)的单药治疗,以及用于拓扑异构酶I抑制剂载荷抗体偶联药物(ADC)预处理的三阴性乳腺癌(TNBC)的单药治疗。9MW2821已获得国家药品监督管理局药品审评中心(CDE)授予的突破性疗法认定,适用于尿路上皮癌的单药治疗和联合治疗。

It is the first Nectin-4-targeting agent to enter Phase III clinical .

这是首款进入III期临床试验的靶向Nectin-4药物。

study

学习

in CC, and the first agent of any target to enter Phase III clinical

在结直肠癌(CC)中,以及首个进入III期临床试验的任何靶点药物

study

学习

specifically in patients with Topo I ADC-pretreated TNBC.

特别是在经拓扑异构酶I抗体偶联药物预处理的三阴性乳腺癌患者中。

The Phase III clinical trials of 9MW2821 for UC monotherapy, UC combination therapy, and CC monotherapy are planned to undergo interim analyses in 2026, and it is expected to, based on the interim analysis data, submit applications for pre-NDA meetings to the

9MW2821用于溃疡性结肠炎(UC)单药治疗、溃疡性结肠炎联合治疗以及克罗恩病(CC)单药治疗的III期临床试验计划于2026年进行中期分析,并预计基于中期分析数据向监管机构提交新药上市申请(NDA)前会议的申请。

CDE

CDE

under the National Medical Products Administration (NMPA).

在国家药品监督管理局(NMPA)的监管下。

Multiple

多个

Phase I/II clinical trials are ongoing in parallel and progressing rapidly. In addition, the TNBC (Topo I ADC-pretreated) monotherapy has entered into Phase Ib clinical trials in the United States.

I/II期临床试验正在并行开展且进展迅速。此外,针对三阴性乳腺癌(Topo I ADC预处理)的单药治疗已在美国进入Ib期临床试验。

About Mabwell

关于迈百瑞

Mabwell (688062.SH, 02493.HK) is an innovation-driven biopharmaceutical company with capabilities spanning the entire pharmaceutical value chain. The company is committed to providing more effective and accessible therapies to meet global medical needs, with a focus on oncology and aging-related diseases.

迈威生物(688062.SH,02493.HK)是一家创新驱动的生物制药公司,具备覆盖医药全产业链的能力。公司致力于提供更有效、更可及的治疗方案,以满足全球医疗需求,重点聚焦于肿瘤学和衰老相关疾病领域。

Mabwell's mission is 'Explore Life, Benefit Health' and its vision is 'Innovation, from Ideas to Reality.' For more information, please visit .

迈百瑞的使命是“探索生命,惠及健康”,愿景是“创新,从理念到现实”。欲了解更多信息,请访问。

www.mabwell.com/en

www.mabwell.com/en

.

。

Forward-Looking Statements

前瞻性陈述

This press release contains forward-looking statements including, but not limited to, the potential safety, efficacy, regulatory review or approval and commercial success of our product candidates and those relating to the Company's product development, clinical studies, clinical and regulatory milestones and timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature.

本新闻稿包含前瞻性陈述,包括但不限于关于我们候选产品的潜在安全性、有效性、监管审查或批准及商业成功的陈述,以及涉及公司产品开发、临床研究、临床和监管里程碑与时间表、市场机会、竞争地位、可能或假设的未来经营业绩、业务战略、潜在增长机会和其他具有预测性质的陈述。

'Forward-looking statements' are statements that are not historical facts and involve a number of risks and uncertainties, which may cause actual results to be materially different from any future results expressed or implied in the forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, 'expect,' 'anticipate,' 'intend,' 'plan,' 'believe,' 'estimate,' 'potential,' 'predict,' 'project,' 'should,' 'would,' and similar expressions and the negatives of those terms..

“前瞻性陈述”是指非历史事实的陈述,涉及多种风险和不确定性,可能导致实际结果与前瞻性陈述中明示或暗示的任何未来结果存在重大差异。此类陈述可通过使用前瞻性用语来识别,包括但不限于“期望”、“预计”、“打算”、“计划”、“相信”、“估计”、“可能”、“预测”、“规划”、“应当”、“将会”以及类似表述和这些术语的否定形式。

Forward-looking statements are based on the Company's current expectations and assumptions. Forward-looking statements are subject to a number of risks, uncertainties, and other factors, many of which are beyond the Company's control, including, but not limited to: environment; politic; economy; society; legislation; our dependence on our product candidates, most of which are still in preclinical or various stages of clinical development; our reliance on third-party vendors, such as contract research organizations and contract manufacturing organizations; the uncertainties inherent in clinical testing; our ability to complete required clinical trials for our product candidates and obtain approval from regulatory authorities for our product candidates; our ability to protect our intellectual property; the loss of any executive officers or key personnel.

前瞻性陈述基于本公司当前的预期和假设。前瞻性陈述受多种风险、不确定性及其他因素的影响,其中许多因素超出本公司的控制范围,包括但不限于:环境、政治、经济、社会、立法;我们对候选产品的依赖,其中大多数仍处于临床前或不同阶段的临床开发中;我们对第三方供应商(如合同研究组织和合同生产组织)的依赖;临床试验中固有的不确定性;我们完成候选产品所需临床试验并获得监管机构批准的能力;我们保护知识产权的能力;以及任何高级管理人员或关键人员的流失。

In case one or more of these risks or uncertainties deteriorate, or any assumptions are incorrect, the actual results may be seriously inconsistent with the stated results..

如果上述一项或多项风险或不确定性恶化,或任何假设不正确,实际结果可能与所述结果严重不符。

The Company cautions all the persons not to place undue reliance on any such forward-looking statements, which speaks only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the applicable Stock authority to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

本公司提醒所有人士,切勿过度依赖任何此类前瞻性陈述,这些陈述仅截至本新闻稿发布之日有效。除法律和适用证券监管机构规则明确要求的以外,本公司不承担任何公开更新或修订任何此类陈述的义务,以反映预期变化,或反映此类陈述所基于的事件、条件或情况的变化,或可能影响实际结果与前瞻性陈述中所述结果存在差异的可能性的变化。

All forward-looking descriptions, figures and assumptions in this press release are applicable to this statement..

本新闻稿中所有前瞻性描述、数据和假设均适用于本声明。

SOURCE Mabwell

来源 迈威

21

二十一

%

%

more press release views with

更多新闻稿浏览量,通过

Request a Demo

申请演示